Stockscreener 앱 받기
0.65
2.29%
-0.0255
Pavmed Inc 주식(PAVM)의 최신 뉴스
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - Longview News-Journal
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
PAVmed outlines strategic milestones for 2025, including Veris implantable device submission - MSN
Pavmed’s Strategic Growth and Financial Challenges - MSN
PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Call Transcript - Insider Monkey
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PR Newswire
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability - Yahoo
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
PAVmed Reports Strong Q4 Results and Strategic Progress - TipRanks
Earnings call transcript: PAVmed Q4 2024 reports net income boost - Investing.com India
Earnings call transcript: PAVmed Q4 2024 reports net income boost By Investing.com - Investing.com South Africa
PAVmed Inc Surpasses Q4 2024 Revenue Estimates with $1.2 Million, Driven by Record EsoGuard Test Volume - GuruFocus
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Placera.se
PAVmed Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PAVmed Achieves Triple Win: Record Tests, Insurance Coverage, Positive Income - Stock Titan
Lucid Diagnostics Reports Strong Growth and Future Plans - TipRanks
Lucid Diagnostics Achieves 84% Growth: EsoGuard Tests Hit All-Time High as Insurance Coverage Expands - Stock Titan
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening - The Malaysian Reserve
Lucid Diagnostics Announces Updated National Comprehensive Cance - GuruFocus
Major Breakthrough: NCCN Backs New Esophageal Cancer Testing Method, Insurance Coverage Expected to Expand - Stock Titan
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - BioSpace
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® - GuruFocus.com
Clinical Study: New EsoGuard Test Detects Esophageal Cancer Risk 140% More Effectively - StockTitan
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - The Malaysian Reserve
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test – Company AnnouncementFT.com - Financial Times
Major Breakthrough: Lucid Diagnostics Secures Game-Changing Insurance Coverage for Cancer Test - Stock Titan
Lucid Diagnostics Executes First Concierge Medicine Contract wit - GuruFocus.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Pri - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 - Longview News-Journal
PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call - Stock Titan
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - BioSpace
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow - Crain's New York Business
PAVmed, Inc. to Host Earnings Call - ACCESS Newswire
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - BioSpace
Lucid Diagnostics secures $15.3 million in stock offering By Investing.com - Investing.com Australia
Lucid Diagnostics secures $15.3 million in stock offering - Investing.com
Lucid Diagnostics secures $15.3 million in stock sale By Investing.com - Investing.com Australia
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering - The Eastern Progress Online
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Insulet (NASDAQ:PODD) & PAVmed (NASDAQ:PAVM) Head-To-Head Review - Defense World
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus.com
Lucid Diagnostics ends "at the market" equity offering By Investing.com - Investing.com South Africa
Lucid Diagnostics ends "at the market" equity offering - Investing.com India
Lucid Diagnostics secures $15.3 million in stock sale - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Short Interest Update - Defense World
Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21SEC Filing - Marketscreener.com
Can Lucid's Cancer Test Reach Millions More Patients? NIH Invests $8M to Find Out - StockTitan
0.62%
0.92%
자본화:
|
볼륨(24시간):